Capricor Therapeutics Stock Analysis

CAPR Stock  USD 6.82  0.30  4.60%   
Capricor Therapeutics is undervalued with Real Value of 15.58 and Target Price of 42.13. The main objective of Capricor Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Capricor Therapeutics is worth, separate from its market price. There are two main types of Capricor Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Capricor Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Capricor Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Capricor Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Capricor Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Capricor Therapeutics was currently reported as 2.8. The company recorded a loss per share of 1.42. Capricor Therapeutics last dividend was issued on the 5th of June 2019. The entity had 1:10 split on the 5th of June 2019. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. The company was founded in 2005 and is headquartered in San Diego, California. Capricor Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people. For more info on Capricor Therapeutics please contact the company at 858 727 1755 or go to https://www.capricor.com.

Capricor Therapeutics Investment Alerts

Capricor Therapeutics generated a negative expected return over the last 90 days
Capricor Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 22.27 M. Net Loss for the year was (40.47 M) with loss before overhead, payroll, taxes, and interest of (40.42 M).
Capricor Therapeutics currently holds about 51.42 M in cash with (40 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11.
Capricor Therapeutics has a very weak financial position based on the latest SEC disclosures
Roughly 17.0% of the company shares are held by company insiders
Latest headline from gurufocus.com: Levi Korsinsky Announces the Filing of a Securities Class Action on Behalf of Capricor ...

Capricor Therapeutics Upcoming and Recent Events

20th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Capricor Largest EPS Surprises

Earnings surprises can significantly impact Capricor Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-12
2020-09-30-0.18-0.2-0.0211 
2022-11-10
2022-09-30-0.29-0.260.0310 
2023-11-14
2023-09-30-0.29-0.250.0413 
View All Earnings Estimates

Capricor Therapeutics Environmental, Social, and Governance (ESG) Scores

Capricor Therapeutics' ESG score is a quantitative measure that evaluates Capricor Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Capricor Therapeutics' operations that may have significant financial implications and affect Capricor Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Capricor Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Pier Capital, Llc2025-03-31
354.2 K
Black Diamond Financial, Llc2025-03-31
277.7 K
Superstring Capital Management Lp2025-03-31
241.2 K
Avidity Partners Management Lp2025-03-31
239 K
Millennium Management Llc2025-03-31
222.1 K
Squarepoint Ops Llc2025-03-31
171.2 K
Nuveen Asset Management, Llc2024-12-31
169.1 K
Susquehanna International Group, Llp2025-03-31
169 K
Jump Financial Llc2025-03-31
163 K
Blackrock Inc2025-03-31
2.9 M
Vanguard Group Inc2025-03-31
2.3 M
Note, although Capricor Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Capricor Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 298.01 M.

Capricor Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.24)(0.25)
Return On Capital Employed(0.28)(0.30)
Return On Assets(0.24)(0.25)
Return On Equity(0.28)(0.26)

Management Efficiency

Capricor Therapeutics has return on total asset (ROA) of (0.3524) % which means that it has lost $0.3524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7539) %, meaning that it created substantial loss on money invested by shareholders. Capricor Therapeutics' management efficiency ratios could be used to measure how well Capricor Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/23/2025, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Capricor Therapeutics' Total Assets are relatively stable compared to the past year. As of 07/23/2025, Non Current Assets Total is likely to grow to about 7.5 M, while Intangible Assets are likely to drop slightly above 2.4 M.
Last ReportedProjected for Next Year
Book Value Per Share 4.13  3.92 
Tangible Book Value Per Share 4.13  3.92 
Enterprise Value Over EBITDA(11.57)(12.15)
Price Book Value Ratio 3.34  3.51 
Enterprise Value Multiple(11.57)(12.15)
Price Fair Value 3.34  3.51 
Enterprise Value476.2 M500 M
Effective leadership at Capricor Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Operating Margin
(3.30)
Beta
0.825
Return On Assets
(0.35)
Return On Equity
(0.75)

Technical Drivers

As of the 23rd of July, Capricor Therapeutics shows the Standard Deviation of 10.1, risk adjusted performance of 0.0052, and Mean Deviation of 6.91. Capricor Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Capricor Therapeutics variance and potential upside to decide if Capricor Therapeutics is priced correctly, providing market reflects its regular price of 6.82 per share. Given that Capricor Therapeutics has information ratio of (0.02), we suggest you to validate Capricor Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Capricor Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Capricor Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

Capricor Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Capricor Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Capricor Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Capricor Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dunbar George W Jr over two months ago
Disposition of 750 shares by Dunbar George W Jr of Capricor Therapeutics at 1. subject to Rule 16b-3
 
Auwaerter Paul Gisbert over three months ago
Acquisition by Auwaerter Paul Gisbert of 5000 shares of Capricor Therapeutics at 2.84 subject to Rule 16b-3
 
Collier Earl M Jr over three months ago
Disposition of 750 shares by Collier Earl M Jr of Capricor Therapeutics at 1. subject to Rule 16b-3
 
Dunbar George W Jr over three months ago
Disposition of 750 shares by Dunbar George W Jr of Capricor Therapeutics at 1. subject to Rule 16b-3
 
Collier Earl M Jr over three months ago
Acquisition by Collier Earl M Jr of 3240 shares of Capricor Therapeutics at 14.96 subject to Rule 16b-3
 
Collier Earl M Jr over three months ago
Acquisition by Collier Earl M Jr of 750 shares of Capricor Therapeutics at 1. subject to Rule 16b-3
 
Auwaerter Paul Gisbert over six months ago
Acquisition by Auwaerter Paul Gisbert of 1440 shares of Capricor Therapeutics at 14.96 subject to Rule 16b-3
 
Dunbar George W Jr over six months ago
Acquisition by Dunbar George W Jr of 8310 shares of Capricor Therapeutics subject to Rule 16b-3
 
Litvack Frank over six months ago
Disposition of 20391 shares by Litvack Frank of Capricor Therapeutics at 1.1 subject to Rule 16b-3
 
Kelliher Mike over six months ago
Acquisition by Kelliher Mike of 30000 shares of Capricor Therapeutics at 5.12 subject to Rule 16b-3
 
Nippon Shinyaku Co Ltd over six months ago
Acquisition by Nippon Shinyaku Co Ltd of 2798507 shares of Capricor Therapeutics at 5.36 subject to Rule 16b-3
 
Manzo Louis over six months ago
Acquisition by Manzo Louis of 37770 shares of Capricor Therapeutics subject to Rule 16b-3

Capricor Therapeutics Outstanding Bonds

Capricor Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Capricor Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Capricor bonds can be classified according to their maturity, which is the date when Capricor Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Capricor Therapeutics Predictive Daily Indicators

Capricor Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Capricor Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Capricor Therapeutics Corporate Filings

8K
11th of July 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
16th of June 2025
Other Reports
ViewVerify
8K
27th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10Q
14th of May 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
13th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
30th of April 2025
Other Reports
ViewVerify
9th of April 2025
Other Reports
ViewVerify
8K
8th of April 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Capricor Therapeutics Forecast Models

Capricor Therapeutics' time-series forecasting models are one of many Capricor Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Capricor Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Capricor Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Capricor Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Capricor shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Capricor Therapeutics. By using and applying Capricor Stock analysis, traders can create a robust methodology for identifying Capricor entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(1.82)(1.91)
Operating Profit Margin(1.91)(2.01)
Net Loss(1.82)(1.91)
Gross Profit Margin 1.03  0.92 

Current Capricor Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Capricor analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Capricor analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
42.13Strong Buy8Odds
Capricor Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Capricor analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Capricor stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Capricor Therapeutics, talking to its executives and customers, or listening to Capricor conference calls.
Capricor Analyst Advice Details

Capricor Stock Analysis Indicators

Capricor Therapeutics stock analysis indicators help investors evaluate how Capricor Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Capricor Therapeutics shares will generate the highest return on investment. By understating and applying Capricor Therapeutics stock analysis, traders can identify Capricor Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow14.7 M
Common Stock Shares Outstanding35.2 M
Total Stockholder Equity145.5 M
Total Cashflows From Investing Activities-116.2 M
Property Plant And Equipment Net6.9 M
Cash And Short Term Investments151.5 M
Cash11.3 M
Net Debt-9.8 M
50 Day M A10.0306
Total Current Liabilities21 M
Other Operating Expenses64.8 M
Non Current Assets Total7.1 M
Non Currrent Assets Other221.7 K
Stock Based Compensation9.8 M

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.